Fermenta Biotech Q3FY26: Consolidated Revenue Down 11% YoY, 9M Growth at 25%
Fermenta Biotech's Q3FY26 results showed mixed performance with quarterly consolidated revenue declining 11% to ₹140.47 crore, but strong nine-month growth of 25% to ₹421.17 crore. The Vitamin D3 segments led growth with human nutrition up 51% and animal nutrition up 46% for the nine-month period.
*this image is generated using AI for illustrative purposes only.
Fermenta Biotech Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showing mixed performance with quarterly revenue decline offset by strong nine-month growth. The Board of Directors approved these results at their meeting held on February 9, 2026, with regulatory compliance filing completed on February 10, 2026.
Quarterly Consolidated Performance
The third quarter showed challenging performance with consolidated revenue declining year-on-year but demonstrating sequential improvement from the previous quarter.
| Metric | Q3FY26 | Q3FY25 | Change (%) |
|---|---|---|---|
| Consolidated Revenue | ₹140.47 crore | ₹158.70 crore | -11% |
| Profit Before Tax | ₹19.68 crore | ₹45.34 crore | -57% |
| Net Profit After Tax | ₹12.02 crore | ₹37.89 crore | -68% |
| Basic EPS | ₹4.90 | ₹12.71 | -61% |
| Diluted EPS | ₹4.87 | ₹12.71 | -62% |
Nine-Month Consolidated Results
The company delivered impressive consolidated performance for the nine-month period, with significant growth across key metrics driven primarily by the Vitamin D3 human nutrition segment.
| Parameter | 9MFY26 | 9MFY25 | Growth (%) |
|---|---|---|---|
| Consolidated Revenue | ₹421.17 crore | ₹337.55 crore | +25% |
| Profit Before Tax | ₹71.85 crore | ₹51.23 crore | +40% |
| Net Profit After Tax | ₹51.65 crore | ₹43.08 crore | +20% |
| Basic EPS | ₹18.58 | ₹14.67 | +27% |
| Diluted EPS | ₹18.47 | ₹14.67 | +26% |
Standalone Financial Performance
The standalone operations also reflected similar trends with quarterly challenges but strong nine-month performance.
| Metric | Q3FY26 | 9MFY26 | 9MFY25 | 9M Growth (%) |
|---|---|---|---|---|
| Revenue | ₹117.67 crore | ₹358.18 crore | ₹316.29 crore | +13% |
| Profit Before Tax | ₹18.70 crore | ₹62.19 crore | ₹46.45 crore | +34% |
| Net Profit After Tax | ₹11.76 crore | ₹42.71 crore | ₹38.30 crore | +12% |
Business Segment Performance
The nutrition business demonstrated strong growth momentum, particularly in the Vitamin D3 segments, with human nutrition volumes growing 46% and animal nutrition volumes increasing 52% during the nine-month period.
| Segment | 9MFY26 Revenue | 9MFY25 Revenue | YoY Change (%) |
|---|---|---|---|
| Vitamin D3 - Human Nutrition | ₹230.80 crore | ₹152.80 crore | +51% |
| Vitamin D3 - Animal Nutrition | ₹85.50 crore | ₹58.70 crore | +46% |
| Other APIs and Intermediates | ₹29.50 crore | ₹25.60 crore | +15% |
| Green Chemistry Solutions/Enzymes | ₹9.00 crore | ₹5.50 crore | +64% |
| Environmental Solutions | ₹18.40 crore | ₹13.60 crore | +35% |
Regulatory Compliance and Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published its unaudited financial results in Business Standard (English) and Sakal (Marathi) newspapers dated February 10, 2026. The regulatory filing was completed by Company Secretary & Head - Legal Varadvinayak Khambete, confirming compliance with all disclosure requirements.
Historical Stock Returns for Fermenta Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.50% | -6.54% | +9.77% | +63.63% | +63.63% | +63.63% |
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
